Key terms
About ADAP
Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ADAP news
Apr 16
2:56am ET
Maintaining Buy Rating on Adaptimmune Therapeutics Post-Genentech Collaboration Termination
Apr 16
2:50am ET
Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Immunic (IMUX)
Mar 13
4:55am ET
Adaptimmune management to meet with Mizuho
Mar 13
2:30am ET
Analysts Offer Insights on Healthcare Companies: Ocular Therapeutix (OCUL), Adaptimmune Therapeutics (ADAP) and Arcutis Biotherapeutics (ARQT)
Mar 11
1:00am ET
Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP), Elevation Oncology (ELEV) and AC Immune SA (ACIU)
Mar 08
4:34pm ET
Adaptimmune management to meet with Mizuho
Mar 08
10:46am ET
Biotech Alert: Searches spiking for these stocks today
Mar 08
4:55am ET
Adaptimmune management to meet with Truist
Mar 08
1:01am ET
New Share Price & Shareholder Rights Risk for Adaptimmune Therapeutics Plc. – What’s the Latest?
Mar 07
11:55pm ET
Buy Rating Affirmed for Adaptimmune on Strong Clinical Results and Commercial Strategy
Mar 07
12:41pm ET
Adaptimmune upgraded to Buy from Hold at JonesResearch
Mar 07
12:35pm ET
Buy Rating Affirmed for Adaptimmune on Upcoming Milestones and Promising Trial Results
Mar 07
7:13am ET
Adaptimmune management to meet with Truist
Mar 07
7:07am ET
Adaptimmune Therapeutics (ADAP) Receives a Sell from Barclays
Mar 07
6:00am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Insulet (PODD) and Adaptimmune Therapeutics (ADAP)
Mar 01
1:28am ET
Buy Rating Affirmed for Adaptimmune Following Reappointment of Key Executive and Strategic Commercialization Plan
Feb 27
8:22am ET
Adaptimmune Appoints Cintia Piccina as New Chief Commercial Officer
Feb 16
4:28pm ET
Adaptimmune Therapeutics Regains Nasdaq Compliance
Feb 13
5:33am ET
Analysts Are Bullish on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), CymaBay Therapeutics (CBAY)
Feb 02
3:05pm ET
Buy Rating for Adaptimmune Therapeutics Amidst FDA Priority Review and Significant Upside Potential
Feb 02
11:07am ET
Biotech Alert: Searches spiking for these stocks today
Feb 01
11:24am ET
Biotech Alert: Searches spiking for these stocks today
Feb 01
11:14am ET
Adaptimmune says afami-cel BLA accepted for FDA priority review
Apr 12
8:00am ET
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
Mar 27
7:30pm ET
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
Mar 06
2:00am ET
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
Feb 27
3:00am ET
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
Feb 21
11:00am ET
Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
ADAP Financials
Key terms
Ad Feedback
ADAP Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ADAP Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
